Kobayashi Pharmaceutical

Kobayashi Pharmaceutical, the Japanese company at the center of a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer valued at more than ¥500 billion. The news comes as the firm continues to face fallout over its beni-koji (red yeast rice) supplements. Reports of a potential acquisition are drawing attention to the company's future ownership and accountability over the scandal.